1. K-State home
  2. »DCM
  3. »K-State News
  4. »News
  5. »Kansas State University's CEEZAD receives $2.3 million grant for vaccine research

K-State News

K-State News
Kansas State University
128 Dole Hall
1525 Mid-Campus Dr North
Manhattan, KS 66506

785-532-2535
785-532-7355 fax
media@k-state.edu

Kansas State University's CEEZAD receives $2.3 million grant for vaccine research

Thursday, Aug. 4, 2016 

 

MANHATTAN — The Center of Excellence for Emerging Zoonotic and Animal Diseases, or CEEZAD, at Kansas State University will use a $2.3 million federal grant to study the safety in livestock of a newly developed vaccine to protect humans from the Ebola Zaire virus.

The grant is from the Defense Threat Reduction Agency in the U.S. Department of Defense through a collaboration with the commercial firm NewLink Genetics. A $100,000 matching contribution from the state of Kansas' NBAF Transition Funds brings the total project funding to $2.4 million.

The university's Biosecurity Research Institute will be used to conduct the project.

The vaccine is called VSV-ZEBOV; VSV stands for Vesicular Stomatitis Virus, and ZEBOV is the acronym for the Zaire strain of Ebola virus, the deadliest strain of Ebola virus that causes Ebola disease in humans. The vaccine uses the vesicular stomatitis virus to carry a small, harmless piece of the Ebola virus that immunizes a vaccinated person. The Ebola virus is thought to be transmitted to people from an as-yet unidentified wild animal reservoir, and then spreads in the human population through human-to-human transmission. The average disease case fatality rate is around 50 percent, but has varied from 25 percent to 90 percent in various outbreaks.

Jürgen Richt, regents distinguished professor at Kansas State University and director of the Center of Excellence for Emerging and Zoonotic Animal Diseases, will be the principal investigator for the project.

"We are very excited to begin research to test the safety of this vaccine, the only efficacious Ebola virus vaccine available," Richt said. "As the world saw with the deadly 2014 outbreak in West Africa, Ebola is one of the most serious emerging zoonotic threats to humans."

Richt also expressed appreciation for the contribution from the state's NBAF fund for the work. NBAF stands for the National Bio and Agro-defense Facility, which is the nation's premiere animal disease research facility that is currently under construction adjacent to the Kansas State University campus in Manhattan.

Zoonotic diseases are those capable of being transmitted from animals to humans and vice versa. It is thought that Ebola virus, which was first identified in 1976, is introduced into the human population through close contact with infected animals such as chimpanzees, gorillas, bats, monkeys, and maybe antelope and porcupines. It is also possible that the Ebola virus can be transmitted through sexual contact involving already-infected persons. The Zaire species of Ebola virus is one of five species that have been identified, and has been associated with large disease outbreaks in Africa — including the 2014 West African outbreak, which infected an estimated 28,600 people and resulted in more than 11,000 deaths.

No infectious Ebola virus will be used in the Biosecurity Research Institute during the studies. The work will provide information to supplement the overall safety of the VSV-ZEBOV vaccine.

The Center of Excellence for Emerging and Zoonotic Animal Diseases is a U.S. Department of Homeland Security Center of Excellence established in 2010 at Kansas State University's College of Veterinary Medicine.

Source

Jürgen A. Richt
785-532- 2793
jricht@vet.k-state.edu

Pronouncer

Jürgen Richt is YUR-gen Rickt

Website

http://www.ceezad.org

Photo

Download the following photo.

Mary Kohn

Kansas State University's Jürgen Richt,regents distinguished professor and director of the Center of Excellence for Emerging Zoonotic and Animal Diseases, is the principal investigator of a $2.3 million grant from the Defense Threat Reduction Agency to study if a newly developed vaccine for humans to protect against the Ebola Zaire virus is also safe to use in livestock.

Written by

Bill Felber
785-532-2793

At a glance

Jürgen Richt,regents distinguished professor and director of the Center of Excellence for Emerging Zoonotic and Animal Diseases at Kansas State University, is the principal investigator on a project studying if a newly developed vaccine for the Ebola Zaire virus for humans would be safe for use in livestock.